Tianhong CNI BIOMEDICINE ETF(159859) Rises 2.30% Intraday,Institutions Indicate API Sector May See Price Hike Opportunities

NewTimeSpace News: As of 13:44 on March 24, 2026, the CSI Biomedical Index (399441) surged 2.14%. Among its constituent stocks, Dizhe Pharmaceutical rose 7.63%, WuXi AppTec climbed 5.81%, Junshi Biosciences advanced 4.73%, and SinoCellular Technology, Asymchem and other individual stocks followed the upward trend. TheTianhong CNI BIOMEDICINE ETF(159859) rose 2.30% to a latest price of RMB 0.36. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

In terms of liquidity, theTianhong CNI BIOMEDICINE ETFrecorded an intraday turnover rate of 2.72% with a trading volume of RMB 106 million. Over a longer timeframe, as of March 23, the average daily trading volume of theTianhong CNI BIOMEDICINE ETFstood at RMB 129 million in the past week, ranking first among comparable funds.

In terms of scale, theTianhong CNI BIOMEDICINE ETFsaw a notable growth of RMB 47.7482 million in scale over the past month, with the newly added scale ranking in the top third among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of theTianhong CNI BIOMEDICINE ETFhit 10.93 billion shares, a new high in the past year, ranking in the top third among comparable funds. (Data source: Wind)

In terms of capital inflows, theTianhong CNI BIOMEDICINE ETFhas seen consecutive net capital inflows for 9 consecutive days. It recorded a maximum single-day net inflow of RMB 115 million, with a total net inflow of RMB 250 million and an average daily net inflow of RMB 27.7719 million. (Data source: Wind)

Data showed that leveraged funds have been continuously building positions in the ETF. The net margin purchase volume of theTianhong CNI BIOMEDICINE ETFsince the start of this month reached RMB 2.9251 million, with the latest margin balance standing at RMB 218 million. (Data source: Wind)

In terms of earnings capacity, as of March 23, 2026, since its inception, theTianhong CNI BIOMEDICINE ETFhas achieved a maximum monthly return of 27.87%, a longest consecutive monthly gain streak of 5 months with a cumulative increase of 31.58% during the streak, and an average monthly return of 5.50% in positive months. As of March 23, 2026, theTianhong CNI BIOMEDICINE ETFhas delivered an annualized excess return of 1.91% over the benchmark since its establishment.

In terms of drawdown, as of March 23, 2026, theTianhong CNI BIOMEDICINE ETFhad a relative drawdown of 0.05% against the benchmark since the start of the year, posting the smallest drawdown among comparable funds.

In terms of fees, theTianhong CNI BIOMEDICINE ETFhas a management fee rate of 0.50% and a custodian fee rate of 0.10%, the lowest fee level among comparable funds.

In terms of tracking accuracy, as of March 23, 2026, theTianhong CNI BIOMEDICINE ETFhad a tracking error of 0.012% in the past three months, boasting the highest tracking accuracy among comparable funds.

TheTianhong CNI BIOMEDICINE ETFclosely tracks the CSI Biomedical Index. The index takes listed companies engaged in the biomedical industry on the Shanghai, Shenzhen and Beijing Stock Exchanges as its sample universe, selects the top 30 securities as index constituent stocks based on a comprehensive ranking of market capitalization and liquidity. It reflects the overall operation of the biomedical industry and provides the market with an index investment target for the sub-sector.

Data showed that as of February 27, 2026, the top 10 weight stocks of the CSI Biomedical Index (399441) were WuXi AppTec, Fosun Pharma, Tigermed, Shanghai RAAS Blood Products, Changchun High-tech, Pharmaron Beijing, Gan & Lee Pharmaceuticals, Bio-Thera Solutions, Asymchem and Walvax Biotechnology in sequence, with the combined weight of the top 10 stocks accounting for 55.33%. (The stocks listed above are only constituent stocks of the index and do not constitute any specific investment recommendation.)

SINOLINK SECURITIES stated that affected by the rising costs of upstream raw materials, downstream active pharmaceutical ingredient (API) products may see price hike opportunities. API prices have been running at a low level for a long time and customer inventory levels are low. Once prices are raised, the uptrend is expected to be highly sustainable. Investors may pay attention to the profit elasticity brought by the price increase in the follow-up.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.